Core Insights - The company Wanbangde is making significant progress in the development of new drugs for Alzheimer's disease, particularly with its controlled-release tablet of Huperzine A (FN12), which is currently in the II/III phase of clinical trials [1][2] - The drug has shown promising safety and efficacy results, with the potential to improve cognitive function in patients [1] - Wanbangde is also expanding its product portfolio in the peptide drug sector, focusing on new compounds that target various mechanisms, including those related to Alzheimer's disease [3] Group 1: Alzheimer's Disease Drug Development - Wanbangde has been dedicated to Alzheimer's disease drug research for many years, aiming to develop new treatment options for patients globally [1] - The controlled-release tablet of Huperzine A is part of the largest known Alzheimer's disease registration study in China, with collaboration from over 50 research institutions [2] - Preliminary studies indicate that Huperzine A can significantly enhance cognitive function and has multiple beneficial effects, including anti-inflammatory and neuroprotective properties [1][2] Group 2: Peptide Drug Research - The company is developing a new class of peptide drugs that have shown excellent results in preclinical animal studies, including weight loss and improvements in diabetes-related metrics [3] - The peptide drugs have received orphan drug designation from the FDA, indicating their potential for treating rare diseases [3] - Wanbangde is also exploring new targets and mechanisms for Alzheimer's disease treatment through its peptide drug research, aiming to establish a strong position in the global Alzheimer's drug development landscape [3]